Metagenomi (MGX) Current Deferred Revenue (2023 - 2025)
Historic Current Deferred Revenue for Metagenomi (MGX) over the last 3 years, with Q3 2025 value amounting to $12.9 million.
- Metagenomi's Current Deferred Revenue fell 5559.84% to $12.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.9 million, marking a year-over-year decrease of 5559.84%. This contributed to the annual value of $22.8 million for FY2024, which is 5264.63% down from last year.
- Metagenomi's Current Deferred Revenue amounted to $12.9 million in Q3 2025, which was down 5559.84% from $18.9 million recorded in Q2 2025.
- Metagenomi's 5-year Current Deferred Revenue high stood at $48.3 million for Q1 2024, and its period low was $12.9 million during Q3 2025.
- Moreover, its 3-year median value for Current Deferred Revenue was $27.3 million (2024), whereas its average is $29.8 million.
- Examining YoY changes over the last 5 years, Metagenomi's Current Deferred Revenue showed a top increase of 4256.0% in 2025 and a maximum decrease of 5559.84% in 2025.
- Metagenomi's Current Deferred Revenue (Quarter) stood at $48.1 million in 2023, then plummeted by 52.65% to $22.8 million in 2024, then tumbled by 43.33% to $12.9 million in 2025.
- Its last three reported values are $12.9 million in Q3 2025, $18.9 million for Q2 2025, and $25.5 million during Q1 2025.